1,890 results on '"Cooper, Mark E"'
Search Results
2. Expanding the UW (unconventional warfare) reach
3. Urine Albumin-Creatinine Ratio Variability in People With Type 2 Diabetes: Clinical and Research Implications
4. Empagliflozin and Rapid Kidney Function Decline Incidence in Type 2 Diabetes: An Exploratory Analysis From the EMPA-REG OUTCOME Trial
5. Glucagon-like peptide-1 receptor signaling modifies the extent of diabetic kidney disease through dampening the receptor for advanced glycation end products–induced inflammation
6. Novel pharmacological interventions for diabetic kidney disease
7. Circulating epigenomic biomarkers correspond with kidney disease susceptibility in high-risk populations with type 2 diabetes mellitus
8. Clinical trials with reno-vascular end points in patients with diabetes: Changing the scenario over the past 20 years
9. The postprandial actions of GLP-1 receptor agonists: The missing link for cardiovascular and kidney protection in type 2 diabetes
10. Low- and middle-income countries demonstrate rapid growth of type 2 diabetes: an analysis based on Global Burden of Disease 1990–2019 data
11. Prognostic value of metabolic syndrome in renal structural changes in type 2 diabetes
12. Inhibition of pancreatic EZH2 restores progenitor insulin in T1D donor
13. The Role of Activator Protein-1 Complex in Diabetes-Associated Atherosclerosis: Insights From Single-Cell RNA Sequencing.
14. To target cellular senescence in diabetic kidney disease: the known and the unknown.
15. Pro-resolving lipid mediators: regulators of inflammation, metabolism and kidney function
16. Endothelial NOX5 Obliterates the Reno-Protective Effect of Nox4 Deletion by Promoting Renal Fibrosis via Activation of EMT and ROS-Sensitive Pathways in Diabetes
17. Hypoglycemia and Cardiovascular Outcomes in the CARMELINA and CAROLINA Trials of Linagliptin
18. YB-1: the Jekyll and Hyde of kidney disease?
19. Abstract 12404: Assessment Of Associations Between Hypoglycemia And Cardiovascular Outcomes In The Randomized CARMELINA And CAROLINA Trials Of The Antihyperglycemic Medication Linagliptin
20. Comparison of Circulating Biomarkers in Predicting Diabetic Kidney Disease Progression With Autoantibodies to Erythropoietin Receptor
21. Protective Effect of Inflammasome Activation by Hydrogen Peroxide in a Mouse Model of Septic Shock
22. Clinicopathologic features and prognostic factors in older patients with biopsy-proven diabetic nephropathy
23. Diabetic Retinopathy, Classified Using the Lesion-Aware Deep Learning System, Predicts Diabetic End-Stage Renal Disease in Chinese Patients
24. Is clinical trial data showing positive progress for the treatment of diabetic kidney disease?
25. Deep multi-omic profiling reveals extensive mitochondrial remodeling driven by glycemia in early diabetic kidney disease
26. Novel pharmacological interventions for diabetic kidney disease
27. Solidified glomerulosclerosis, identified using single glomerular proteomics, predicts end-stage renal disease in Chinese patients with type 2 diabetes
28. DNA methylation status correlates with adult β-cell regeneration capacity
29. Empagliflozin modulates renal sympathetic and heart rate baroreflexes in a rabbit model of diabetes
30. Linagliptin and cardiorenal outcomes in Asians with type 2 diabetes mellitus and established cardiovascular and/or kidney disease: subgroup analysis of the randomized CARMELINA® trial
31. Apoptotic Ablation of Platelets Reduces Atherosclerosis in Mice With Diabetes
32. Potential cardiorenal benefits of efpeglenatide in diabetes
33. Pathophysiological Links Between Diabetes and Blood Pressure
34. Cardiovascular Disease and Diabetic Kidney Disease
35. New Glucose-Lowering Agents for Diabetic Kidney Disease
36. SGLT2 inhibitors with cardiovascular benefits: Transforming clinical care in Type 2 diabetes mellitus
37. Transient Intermittent Hyperglycemia Accelerates Atherosclerosis by Promoting Myelopoiesis
38. Nox (NADPH Oxidase) 1, Nox4, and Nox5 Promote Vascular Permeability and Neovascularization in Retinopathy
39. Transactivation of RAGE mediates angiotensin-induced inflammation and atherogenesis
40. Endothelial or vascular smooth muscle cell-specific expression of human NOX5 exacerbates renal inflammation, fibrosis and albuminuria in the Akita mouse
41. The Standard of Care in Type 2 Diabetes: Re-evaluating the Treatment Paradigm
42. An Engineered Nanosugar Enables Rapid and Sustained Glucose‐Responsive Insulin Delivery in Diabetic Mice (Adv. Mater. 21/2023)
43. SGLT2 inhibitors for patients with type 2 diabetes and CKD: a narrative review
44. Acute Increases in Serum Creatinine After Starting Angiotensin-Converting Enzyme Inhibitor-Based Therapy and Effects of its Continuation on Major Clinical Outcomes in Type 2 Diabetes Mellitus: The ADVANCE Trial
45. Haemoglobin glycation index and risk for diabetes-related complications in the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial
46. Supplementary Table 1 from The Association of High-Density Lipoprotein Cholesterol with Cancer Incidence in Type II Diabetes: A Case of Reverse Causality?
47. Reduced methylation correlates with diabetic nephropathy risk in type 1 diabetes
48. Pyridoxamine prevents increased atherosclerosis by intermittent methylglyoxal spikes in the aortic arches of ApoE-/- mice
49. Diet low in advanced glycation end products increases insulin sensitivity in healthy overweight individuals: a double-blind, randomized, crossover trial1–3
50. Hemodynamic effects of the dipeptidyl peptidase-4 inhibitor linagliptin with renin–angiotensin system inhibitors in type 2 diabetic patients with albuminuria
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.